Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. FDA label
Also known as Hydrochlorothiazide (HCTZ)
Hydrochlorothiazide · 1 trial · 1 indication
Steady state was defined as 90-120 minutes post-dose. IGT was defined as a 2 hour plasma glucose \>= 140 and \<= 199 mg/dL during a 75g oral glucose tolerance test at screening.
Steady state was defined as 90-120 minutes post-dose. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening.
Steady state was defined as 90-120 minutes post-dose. NGT participants (FPG \<100 mg/dL \& 2 hour plasma glucose (PG) \<140 mg/dL during a 75g oral glucose tolerance test (OGTT) at screening) were neither Impaired Glucose Tolerant (IGT) nor Impaired Fasting Glucose (IFG). IGT was defined as a 2 hour plasma glucose \>= 140 and \<= 199 mg/dL during a 75g oral glucose tolerance test at screening. IFG was defined as FPG between 100 and 125 mg/dL at screening.
Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes.
| Arm | Type | Description |
|---|---|---|
| Part I, Placebo-HCTZ | EXPERIMENTAL | Placebo in Period 1 followed by HCTZ in Period 2 |
| Part I, HCTZ-Placebo | EXPERIMENTAL | HCTZ in Period 1, followed by placebo in Period 2 |
| Part II, Placebo-ISMN | EXPERIMENTAL | Placebo in Period 1, followed by ISMN in Period 2 |
| Part II, ISMN-Placebo | EXPERIMENTAL | ISMN in Period 1, followed by placebo in Period 2 |
| Name | Type | Description |
|---|---|---|
| Hydrochlorothiazide (HCTZ) | DRUG | HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period. |
| Comparator: Placebo to HCTZ | DRUG | Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period |
| Isosorbide mononitrate (ISMN) | DRUG | ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period |
| Comparator: Placebo to ISMN | DRUG | Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period |
Inclusion Criteria: * Female participants must be post-menopausal * Body Mass Index (BMI) of at least 29 kg/m\^2 * Weight has been stable over the past 3 months * Has never been treated for hypertension or is diagnosed with hypertension taking up to 2 anti-hypertensive medications * Willing to stop...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Hydrochlorothiazide is a small molecule drug developed by Merck & Company, Inc. (MRK) for hypertension in the cardiovascular therapeutic area. It is also known as HCTZ. The drug is in Phase 1 clinical development.
Hydrochlorothiazide is being studied for the treatment of hypertension. It is a small molecule developed by Merck & Company, Inc. (MRK) and is currently in Phase 1 clinical development.
Hydrochlorothiazide targets SLC12A3 and acts as an inhibitor. SLC12A3 is the molecular target of this small molecule drug, which is being developed by Merck & Company, Inc. (MRK) for hypertension.
Hydrochlorothiazide is developed by Merck & Company, Inc., which trades under the ticker MRK. The company is responsible for the clinical development of this small molecule drug for hypertension.
Hydrochlorothiazide is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for the studied indication of hypertension.
Hydrochlorothiazide has been studied in one completed Phase 1 clinical trial, NCT00871871, titled "Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)." The trial enrolled 64 participants with hypertension and was randomized, double-blind, and controlled.
Yes, Hydrochlorothiazide is also known as HCTZ. Both names refer to the same small molecule drug developed by Merck & Company, Inc. (MRK) for hypertension.